New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 28, 2012
11:17 EDTNYMXNymox completes enrollment in U.S. Phase 3 NX02-0017 study of NX-1207
Nymox Pharmaceutical announced completion of patient enrollment in the company's pivotal U.S. Phase 3 NX02-0017 study of NX-1207 for BPH. This study is now closed to further enrollment. Top-line results from the large Phase 3 Study are expected in late 2013. Paul Averback MD, CEO of Nymox said, "Our drug development programs for NX-1207 include pivotal studies in the U.S. and Europe, re-injection studies in the U.S., prostate cancer trials, and other clinical and non-clinical research activities. Over 2000 patients have participated to date in NX-1207 trials. Final completion of enrollment in this major pivotal study is an important milestone in the NX-1207 development pathway. We look forward to further milestones as this and other trials are completed and results are reported."
News For NYMX From The Last 14 Days
Check below for free stories on NYMX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
09:32 EDTNYMXNymox announces positive efficacy results in Phase 3 trial of NX-1207
Nymox announced new positive efficacy data for U.S. Study NX02-0022, the company's repeat injection study of NX-1207 for BPH. Analysis of symptomatic improvement from repeat injection over a 1 to 2 year period showed a mean improvement of 8.2 points in the AUA BPH Symptom Index Score. Evaluation of safety data from this study confirmed that NX-1207 reinjection treatment was well-tolerated by patients, did not impair sexual function, and has not shown any drug-related significant side effects. Participants in the clinical trial consisted of 160 consecutively treated men who had previously completed participation in an NX-1207 trial for BPH and who volunteered for a subsequent open label injection of NX-1207.
July 15, 2014
09:31 EDTNYMXNymox completes enrollment for second BPH re-injection study
Nymox Pharmaceutical announced the closing of enrollment for Study NX02-0022, the company's second re-injection Phase 3 clinical trial of the safety and efficacy of NX-1207 for the treatment of enlarged prostate. The NX02-0022 study enrolled patients who had previously participated in an earlier NX-1207 BPH study, and in the new trial these men received a second open-label injection of NX-1207. The study used a new lyophilized formulation of NX-1207 that has longer stability stored at room temperature. An interim analysis of the new efficacy data from the NX02-0022 study will be reported within the next few weeks.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use